Search Results - "EZEKOWITZ, Michael"

Filling an Important Knowledge Gap: The DOAC Score by Ezekowitz, Michael D., Kamareddine, Mohammed

Get full text

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials by Ruff, Christian T, Dr, Giugliano, Robert P, MD, Braunwald, Eugene, Prof, Hoffman, Elaine B, PhD, Deenadayalu, Naveen, MPH, Ezekowitz, Michael D, Prof, Camm, A John, Prof, Weitz, Jeffrey I, Prof, Lewis, Basil S, Prof, Parkhomenko, Alexander, Prof, Yamashita, Takeshi, Prof, Antman, Elliott M, Prof

“…Summary Background Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the…”
Get full text

The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study by Hijazi, Ziad, Dr, Oldgren, Jonas, PhD, Lindbäck, Johan, MSc, Alexander, John H, Prof, Connolly, Stuart J, Prof, Eikelboom, John W, MD, Ezekowitz, Michael D, Prof, Held, Claes, PhD, Hylek, Elaine M, Prof, Lopes, Renato D, PhD, Siegbahn, Agneta, Prof, Yusuf, Salim, Prof, Granger, Christopher B, Prof, Wallentin, Lars, Prof

“…Summary Background The benefit of oral anticoagulation in atrial fibrillation is based on a balance between reduction in ischaemic stroke and increase in major…”
Get full text

The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) by REILLY, Paul A, LEHR, Thorsten, HAERTTER, Sebastian, CONNOLLY, Stuart J, YUSUF, Salim, EIKELBOOM, John W, EZEKOWITZ, Michael D, NEHMIZ, Gerhard, SUSAN WANG, WALLENTIN, Lars

“…The goal of this study was to analyze the impact of dabigatran plasma concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic…”
Get full text

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation by January, Craig T., MD, PhD, FACC, Wann, L. Samuel, MD, MACC, FAHA, Alpert, Joseph S., MD, FACC, FAHA, Calkins, Hugh, MD, FACC, FAHA, FHRS, Cigarroa, Joaquin E., MD, FACC, Cleveland, Joseph C., MD, FACC, Conti, Jamie B., MD, FACC, FHRS, Ellinor, Patrick T., MD, PhD, FAHA, Ezekowitz, Michael D., MB, ChB, FACC, FAHA, Field, Michael E., MD, FACC, FHRS, Murray, Katherine T., MD, FACC, FAHA, FHRS, Sacco, Ralph L., MD, FAHA, Stevenson, William G., MD, FACC, FAHA, FHRS, Tchou, Patrick J., MD, FACC, Tracy, Cynthia M., MD, FACC, FAHA, Yancy, Clyde W., MD, FACC, FAHA

“…An organized and directed approach to a thorough review of evidence has resulted in the production of clinical practice guidelines that assist clinicians in…”
Get full text

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons by January, Craig T, Wann, L Samuel, Calkins, Hugh, Chen, Lin Y, Cigarroa, Joaquin E, Cleveland, Joseph C, Ellinor, Patrick T, Ezekowitz, Michael D, Field, Michael E, Furie, Karen L, Heidenreich, Paul A, Murray, Katherine T, Shea, Julie B, Tracy, Cynthia M, Yancy, Clyde W

Get full text

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society by January, Craig T, Wann, L Samuel, Calkins, Hugh, Chen, Lin Y, Cigarroa, Joaquin E, Cleveland, Jr, Joseph C, Ellinor, Patrick T, Ezekowitz, Michael D, Field, Michael E, Furie, Karen L, Heidenreich, Paul A, Murray, Katherine T, Shea, Julie B, Tracy, Cynthia M, Yancy, Clyde W

“…Indications for measurement of NOAC serum levels might include: ▪Measurement of drug levels in patients undergoing urgent surgical procedures. ▪Uncovering…”
Get full text

Newly Identified Events in the RE-LY Trial by Reilly, Paul A, Connolly, Stuart J, Yusuf, Salim, Ezekowitz, Michael D, Wallentin, Lars

“…To the Editor: We wish to update our article about the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial (Sept. 17, 2009, issue). 1…”
Get full text

Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial by Goette, Andreas, Prof, Merino, Jose L, Prof, Ezekowitz, Michael D, Prof, Zamoryakhin, Dmitry, MD, Melino, Michael, PhD, Jin, James, PhD, Mercuri, Michele F, MD, Grosso, Michael A, MD, Fernandez, Victor, BS, Al-Saady, Naab, MD, Pelekh, Natalya, MD, Merkely, Bela, Prof, Zenin, Sergey, MD, Kushnir, Mykola, MD, Spinar, Jindrich, Prof, Batushkin, Valeriy, Prof, de Groot, Joris R, MD, Lip, Gregory Y H, Prof

“…Summary Background Edoxaban, an oral factor Xa inhibitor, is non-inferior for prevention of stroke and systemic embolism in patients with atrial fibrillation…”
Get full text

Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial by Wallentin, Lars, Prof, Yusuf, Salim, Prof, Ezekowitz, Michael D, Prof, Alings, Marco, MD, Flather, Marcus, MD, Franzosi, Maria Grazia, PhD, Pais, Prem, Prof, Dans, Antonio, Prof, Eikelboom, John, MD, Oldgren, Jonas, MD, Pogue, Janice, PhD, Reilly, Paul A, PhD, Yang, Sean, MSc, Connolly, Stuart J, Prof

“…Summary Background Effectiveness and safety of warfarin is associated with the time in therapeutic range (TTR) with an international normalised ratio (INR) of…”
Get full text

Atrial Fibrillation Burden: Moving Beyond Atrial Fibrillation as a Binary Entity: A Scientific Statement From the American Heart Association by Chen, Lin Y, Chung, Mina K, Allen, Larry A, Ezekowitz, Michael, Furie, Karen L, McCabe, Pamela, Noseworthy, Peter A, Perez, Marco V, Turakhia, Mintu P

“…Our understanding of the risk factors and complications of atrial fibrillation (AF) is based mostly on studies that have evaluated AF in a binary fashion…”
Get full text

Left Ventricular Thrombi: Uncommon But Clinically Important by Ezekowitz, Michael D., Kurz, Daniel, Kent, Anthony

“…[Display omitted]…”
Get full text

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial by Diener, Hans-Christoph, Prof, Connolly, Stuart J, Prof, Ezekowitz, Michael D, Prof, Wallentin, Lars, Prof, Reilly, Paul A, PhD, Yang, Sean, MSc, Xavier, Denis, MD, Di Pasquale, Giuseppe, Prof, Yusuf, Salim, Prof

“…Summary Background In the Randomised Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, dabigatran reduced occurrence of both stroke and…”
Get full text

2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society by January, Craig T, Wann, L Samuel, Alpert, Joseph S, Calkins, Hugh, Cigarroa, Joaquin E, Cleveland, Jr, Joseph C, Conti, Jamie B, Ellinor, Patrick T, Ezekowitz, Michael D, Field, Michael E, Murray, Katherine T, Sacco, Ralph L, Stevenson, William G, Tchou, Patrick J, Tracy, Cynthia M, Yancy, Clyde W

Get full text

Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association by Kernan, Walter N, Ovbiagele, Bruce, Black, Henry R, Bravata, Dawn M, Chimowitz, Marc I, Ezekowitz, Michael D, Fang, Margaret C, Fisher, Marc, Furie, Karen L, Heck, Donald V, Johnston, S. Claiborne (Clay), Kasner, Scott E, Kittner, Steven J, Mitchell, Pamela H, Rich, Michael W, Richardson, DeJuran, Schwamm, Lee H, Wilson, John A

“…The aim of this updated guideline is to provide comprehensive and timely evidence-based recommendations on the prevention of future stroke among survivors of…”
Get full text

Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: A subgroup analysis of TRENDS by Daoud, Emile G., MD, Glotzer, Taya V., MD, Wyse, D. George, MD, PhD, FHRS, Ezekowitz, Michael D., MD, PhD, Hilker, Christopher, MS, Koehler, Jodi, MS, Ziegler, Paul D., MS

“…Background The temporal relationship between atrial tachyarrhythmias (atrial tachycardia [AT] and atrial fibrillation [AF]) and cerebrovascular events/systemic…”
Get full text

Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation by Wallentin, Lars, Lindbäck, Johan, Eriksson, Niclas, Hijazi, Ziad, Eikelboom, John W, Ezekowitz, Michael D, Granger, Christopher B, Lopes, Renato D, Yusuf, Salim, Oldgren, Jonas, Siegbahn, Agneta

“…Abstract Aims The global COVID-19 pandemic is caused by the SARS-CoV-2 virus entering human cells using angiotensin-converting enzyme 2 (ACE2) as a cell…”
Get full text

Intracranial Hemorrhage in Atrial Fibrillation Patients During Anticoagulation With Warfarin or Dabigatran: The RE-LY Trial by HART, Robert G, DIENER, Hans-Christoph, SEAN YANG, CONNOLLY, Stuart J, WALLENTIN, Lars, REILLY, Paul A, EZEKOWITZ, Michael D, YUSUF, Salim

“…Intracranial hemorrhage is the most devastating complication of anticoagulation. Outcomes associated with different sites of intracranial bleeding occurring…”
Get full text

Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) by Ezekowitz, Michael D, Nagarakanti, Rangadham, Noack, Herbert, Brueckmann, Martina, Litherland, Claire, Jacobs, Mark, Clemens, Andreas, Reilly, Paul A, Connolly, Stuart J, Yusuf, Salim, Wallentin, Lars

“…BACKGROUND:The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) compared dabigatran 150 and 110 mg twice daily with warfarin in 18 113…”
Get full text

Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy by HIJAZI, Ziad, OLDGREN, Jonas, WALLENTIN, Lars, ANDERSSON, Ulrika, CONNOLLY, Stuart J, EZEKOWITZ, Michael D, HOHNLOSER, Stefan H, REILLY, Paul A, VINEREANU, Dragos, SIEGBAHN, Agneta, YUSUF, Salim

“…Cardiac biomarkers are strong predictors of adverse outcomes in several patient populations. We evaluated the prevalence of elevated troponin I and N-terminal…”
Get full text